Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Richard Schilsky

TitleProfessor Emeritus
InstitutionUniversity of Chicago
DepartmentMedicine
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Schilsky RL. Talking the talk about tumor genomic testing. J Natl Cancer Inst. 2019 Nov 01. PMID: 31675090.
      View in: PubMed
    2. Jagsi R, Griffith KA, Jones RD, Krenz C, Gornick M, Spence R, De Vries R, Hawley ST, Zon R, Bolte S, Sadeghi N, Schilsky RL, Bradbury AR. Effect of Public Deliberation on Patient Attitudes Regarding Consent and Data Use in a Learning Health Care System for Oncology. J Clin Oncol. 2019 Dec 01; 37(34):3203-3211. PMID: 31577472.
      View in: PubMed
    3. van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P, Schilsky RL, de Leng WWJ, Huitema ADR, Nuijen B, Nederlof PM, van Herpen CML, de Groot DJA, Devriese LA, Hoeben A, de Jonge MJA, Chalabi M, Smit EF, de Langen AJ, Mehra N, Labots M, Kapiteijn E, Sleijfer S, Cuppen E, Verheul HMW, Gelderblom H, Voest EE. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019 10; 574(7776):127-131. PMID: 31570881.
      View in: PubMed
    4. Bruinooge SS, Sherwood S, Grubbs S, Schilsky RL. Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies. J Oncol Pract. 2019 Nov; 15(11):575-583. PMID: 31386607.
      View in: PubMed
    5. Nass SJ, Cohen MB, Nayar R, Zutter MM, Balogh EP, Schilsky RL, Hricak H, Elenitoba-Johnson KSJ. Improving Cancer Diagnosis and Care: Patient Access to High-Quality Oncologic Pathology. Oncologist. 2019 Oct; 24(10):1287-1290. PMID: 31366725.
      View in: PubMed
    6. Burd A, Schilsky RL, Byrd JC, Levine RL, Papadimitrakopoulou VA, Herbst RS, Redman MW, Druker BJ, Gandara DR. Challenges and approaches to implementing master/basket trials in oncology. Blood Adv. 2019 Jul 23; 3(14):2237-2243. PMID: 31337605.
      View in: PubMed
    7. Kaufman HL, Atkins MB, Subedi P, Wu J, Chambers J, Joseph Mattingly T, Campbell JD, Allen J, Ferris AE, Schilsky RL, Danielson D, Lichtenfeld JL, House L, Selig WKD. The promise of Immuno-oncology: implications for defining the value of cancer treatment. J Immunother Cancer. 2019 May 17; 7(1):129. PMID: 31101066.
      View in: PubMed
    8. Nass SJ, Cogle CR, Brink JA, Langlotz CP, Balogh EP, Muellner A, Siegal D, Schilsky RL, Hricak H. Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging Expertise. J Clin Oncol. 2019 Jul 10; 37(20):1690-1694. PMID: 31050908.
      View in: PubMed
    9. Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, Martini JF, Raynaud J, Mendelsohn J, Batist G, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019 05; 25(5):751-758. PMID: 31011205.
      View in: PubMed
    10. Cherny NI, de Vries EGE, Schilsky RL. Letter to the Editor: When Expertly Applied, ESMO-MCBS and ASCO Net Health Benefit Scores Usually Agree. J Natl Compr Canc Netw. 2019 Apr 01; 17(4):xxi. PMID: 30959465.
      View in: PubMed
    11. Polite BN, Seid JE, Freeman M, Levit LA, Kirkwood MK, Schenkel C, Bruinooge SS, Schilsky RL. State of Cancer Care in America: Reflections on an Inaugural Year. J Oncol Pract. 2019 Apr; 15(4):163-165. PMID: 30856037.
      View in: PubMed
    12. Levit LA, Kim ES, McAneny BL, Nadauld LD, Levit K, Schenkel C, Schilsky RL. Implementing Precision Medicine in Community-Based Oncology Programs: Three Models. J Oncol Pract. 2019 Jun; 15(6):325-329. PMID: 30802151.
      View in: PubMed
    13. Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez-MacGregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE. Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2019 Apr 01; 37(10):834-849. PMID: 30702028.
      View in: PubMed
    14. Cherny NI, de Vries EGE, Dafni U, Garrett-Mayer E, McKernin SE, Piccart M, Latino NJ, Douillard JY, Schnipper LE, Somerfield MR, Bogaerts J, Karlis D, Zygoura P, Vervita K, Pentheroudakis G, Tabernero J, Zielinski C, Wollins DS, Schilsky RL. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. J Clin Oncol. 2019 Feb 01; 37(4):336-349. PMID: 30707056.
      View in: PubMed
    15. Nass SJ, Rothenberg ML, Pentz R, Hricak H, Abernethy A, Anderson K, Gee AW, Harvey RD, Piantadosi S, Bertagnolli MM, Schrag D, Schilsky RL. Accelerating anticancer drug development - opportunities and trade-offs. Nat Rev Clin Oncol. 2018 12; 15(12):777-786. PMID: 30275514.
      View in: PubMed
    16. Tsimberidou AM, Levit LA, Schilsky RL, Averbuch SD, Chen D, Kirkwood JM, McShane LM, Sharon E, Mileham KF, Postow MA. Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. J Clin Oncol. 2019 01 01; 37(1):72-80. PMID: 30339040.
      View in: PubMed
    17. Tsimberidou AM, Levit LA, Schilsky RL, Averbuch SD, Chen D, Kirkwood JM, McShane LM, Sharon E, Mileham KF, Postow MA. Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement. J Immunother Cancer. 2018 10 19; 6(1):108. PMID: 30340549.
      View in: PubMed
    18. Silverman LR, Norton L, Schilsky RL. In Memoriam: James Frederick Holland, 1925 to 2018. J Clin Oncol. 2018 Sep 10; 36(26):2665-2668. PMID: 30052481.
      View in: PubMed
    19. Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KA, Stella PJ, Voest E, Yost KJ, Perlmutter J, Pinto N, Kim ES, Schilsky RL. Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2018; 2018. PMID: 30603737.
      View in: PubMed
    20. Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. Eur J Cancer. 2018 09; 100:35-45. PMID: 29936065.
      View in: PubMed
    21. Kirkwood MK, Hanley A, Bruinooge SS, Garrett-Mayer E, Levit LA, Schenkel C, Seid JE, Polite BN, Schilsky RL. The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey. J Oncol Pract. 2018 07; 14(7):e412-e420. PMID: 29906211.
      View in: PubMed
    22. Polite BN, Seid JE, Levit LA, Kirkwood MK, Schenkel C, Bruinooge SS, Grubbs SS, Kamin DY, Schilsky RL. A New Look at the State of Cancer Care in America. J Oncol Pract. 2018 07; 14(7):397-399. PMID: 29906212.
      View in: PubMed
    23. Schilsky RL. Access versus evidence: The regulators' dilemma. Clin Trials. 2018 06; 15(3):240-242. PMID: 29871504.
      View in: PubMed
    24. Lyman GH, Zon R, Harvey RD, Schilsky RL. Reply to S.D. Lucio. J Clin Oncol. 2018 07 10; 36(20):2127. PMID: 29847292.
      View in: PubMed
    25. Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, Opportunities, and Reality of Biosimilar Medications. N Engl J Med. 2018 May 24; 378(21):2036-2044. PMID: 29791832.
      View in: PubMed
    26. Schilsky RL, Schnipper LE. Hans Christian Andersen and the Value of New Cancer Treatments. J Natl Cancer Inst. 2018 05 01; 110(5):441-442. PMID: 29244175.
      View in: PubMed
    27. Schilsky RL. A New IDEA in Adjuvant Chemotherapy for Colon Cancer. N Engl J Med. 2018 03 29; 378(13):1242-1244. PMID: 29590539.
      View in: PubMed
    28. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Arch Pathol Lab Med. 2018 10; 142(10):1242-1253. PMID: 29504834.
      View in: PubMed
    29. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018 06 01; 36(16):1631-1641. PMID: 29504847.
      View in: PubMed
    30. Schnipper LE, Schilsky RL. Are Value Frameworks Missing the Mark When Considering Long-term Benefits From Immuno-oncology Drugs? JAMA Oncol. 2018 03 01; 4(3):333-334. PMID: 29285543.
      View in: PubMed
    31. Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, Zon R, Francisco M, Green S, Sherwood S, Harvey RD, Schilsky RL. American Society of Clinical Oncology Statement: Biosimilars in Oncology. J Clin Oncol. 2018 04 20; 36(12):1260-1265. PMID: 29443651.
      View in: PubMed
    32. Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran RB, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-Galindo C, Schilsky RL, Sznol M, Westin SN, Burstein H. Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2018 04 01; 36(10):1020-1044. PMID: 29380678.
      View in: PubMed
    33. Moscow JA, Fojo T, Schilsky RL. The evidence framework for precision cancer medicine. Nat Rev Clin Oncol. 2018 03; 15(3):183-192. PMID: 29255239.
      View in: PubMed
    34. Levit LA, Perez RP, Smith DC, Schilsky RL, Hayes DF, Vose JM. Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. J Clin Oncol. 2018 02 20; 36(6):617-623. PMID: 29236570.
      View in: PubMed
    35. Conley RB, Dickson D, Zenklusen JC, Al Naber J, Messner DA, Atasoy A, Chaihorsky L, Collyar D, Compton C, Ferguson M, Khozin S, Klein RD, Kotte S, Kurzrock R, Lin CJ, Liu F, Marino I, McDonough R, McNeal A, Miller V, Schilsky RL, Wang LI. Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus. Cell. 2017 Nov 16; 171(5):982-986. PMID: 29149611.
      View in: PubMed
    36. Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, Uldrick TS, Lichtman SM, Roach N, Beaver JA, Sridhara R, Hesketh PJ, Denicoff AM, Garrett-Mayer E, Rubin E, Multani P, Prowell TM, Schenkel C, Kozak M, Allen J, Sigal E, Schilsky RL. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. J Clin Oncol. 2017 Nov 20; 35(33):3737-3744. PMID: 28968170.
      View in: PubMed
    37. Schilsky RL. Guideposts on the journey to value. Ann Oncol. 2017 10 01; 28(10):2325-2326. PMID: 28961824.
      View in: PubMed
    38. Schlemmer HP, Bittencourt LK, D'Anastasi M, Domingues R, Khong PL, Lockhat Z, Muellner A, Reiser MF, Schilsky RL, Hricak H. Global Challenges for Cancer Imaging. J Glob Oncol. 2018 09; 4:1-10. PMID: 30241164.
      View in: PubMed
    39. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB, Mulkerin DL, Mayer RJ, Blanke C. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 06 20; 317(23):2392-2401. PMID: 28632865.
      View in: PubMed
    40. Schnipper LE, Schilsky RL. Converging on the Value of Value Frameworks. J Clin Oncol. 2017 08 20; 35(24):2732-2734. PMID: 28586244.
      View in: PubMed
    41. Schnipper LE, Schilsky RL. Reply to J.P. Jansen, A. Messori et al, and H.S.L. Jim et al. J Clin Oncol. 2017 04 01; 35(10):1134. PMID: 28165893.
      View in: PubMed
    42. Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017 04 20; 35(12):1341-1367. PMID: 28148207.
      View in: PubMed
    43. Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F. Reply to L. Casadaban et al. J Clin Oncol. 2017 04 20; 35(12):1373-1374. PMID: 28113023.
      View in: PubMed
    44. Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, Mendelsohn J, Kurzrock R. Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. JAMA Oncol. 2016 Nov 01; 2(11):1452-1459. PMID: 27273579.
      View in: PubMed
    45. Schilsky RL. Finding the Evidence in Real-World Evidence: Moving from Data to Information to Knowledge. J Am Coll Surg. 2017 01; 224(1):1-7. PMID: 27989954.
      View in: PubMed
    46. Pang HH, Wang X, Stinchcombe TE, Wong ML, Cheng P, Ganti AK, Sargent DJ, Zhang Y, Hu C, Mandrekar SJ, Redman MW, Manola JB, Schilsky RL, Cohen HJ, Bradley JD, Adjei AA, Gandara D, Ramalingam SS, Vokes EE. Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. J Clin Oncol. 2016 11 20; 34(33):3992-3999. PMID: 27646951.
      View in: PubMed
    47. Agiro A, Ma Q, Acheson AK, Wu SJ, Patt DA, Barron JJ, Malin JL, Rosenberg A, Schilsky RL, Lyman GH. Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer. J Clin Oncol. 2016 11 10; 34(32):3872-3879. PMID: 27646945.
      View in: PubMed
    48. Schilsky R, Davies W. Highlights from the 2016 WIN Symposium, 27-29 June 2016, Paris: personalised therapy beyond next-generation sequencing. Ecancermedicalscience. 2016; 10:669. PMID: 27610195.
      View in: PubMed
    49. Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F. Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). J Clin Oncol. 2016 09 01; 34(25):3047-53. PMID: 27432924.
      View in: PubMed
    50. Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Vose JM, Schilsky RL. Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. J Clin Oncol. 2016 08 20; 34(24):2925-34. PMID: 27247218.
      View in: PubMed
    51. Disch J, Feeley TW, Mason DJ, Schilsky RL, Stovall EL, Nasso SF. Transformation of Health Care - Perspectives of Opinion Leaders. Semin Oncol Nurs. 2016 05; 32(2):172-82. PMID: 27137474.
      View in: PubMed
    52. Jardim DL, Schwaederle M, Lee JJ, Wei C, Mendelsohn J, Schilsky RL, Kurzrock R. Response. J Natl Cancer Inst. 2016 Mar; 108(3):djw001. PMID: 26912651.
      View in: PubMed
    53. Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2016 Mar 20; 34(9):987-1011. PMID: 26846975.
      View in: PubMed
    54. Allegra CJ, Rumble RB, Schilsky RL. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 Summary. J Oncol Pract. 2016 Feb; 12(2):180-1. PMID: 26443838.
      View in: PubMed
    55. Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, Schilsky RL. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol. 2016 Jan 10; 34(2):179-85. PMID: 26438111.
      View in: PubMed
    56. Schilsky RL, Wehrwein P. Gains Against Cancer, But Enter 'Financial Toxicity'. Manag Care. 2015 Oct; 24(10):46-7, 52-4. PMID: 26665715.
      View in: PubMed
    57. Jardim DL, Fontes Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst. 2015 Nov; 107(11). PMID: 26378224.
      View in: PubMed
    58. Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015 Nov 10; 33(32):3817-25. PMID: 26304871.
      View in: PubMed
    59. Schilsky RL. Highlights from the 2015 WIN Symposium: novel targets, innovative agents, and advanced technologies-a WINning strategy? Ecancermedicalscience. 2015; 9:564. PMID: 26316885.
      View in: PubMed
    60. Kim ES, Bernstein D, Hilsenbeck SG, Chung CH, Dicker AP, Ersek JL, Stein S, Khuri FR, Burgess E, Hunt K, Ivy P, Bruinooge SS, Meropol N, Schilsky RL. Modernizing Eligibility Criteria for Molecularly Driven Trials. J Clin Oncol. 2015 Sep 01; 33(25):2815-20. PMID: 26195710.
      View in: PubMed
    61. Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Schilsky RL. American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. J Clin Oncol. 2015 Aug 10; 33(23):2563-77. PMID: 26101248.
      View in: PubMed
    62. Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget. 2015 Jun 10; 6(16):14139-52. PMID: 25944621.
      View in: PubMed
    63. Tejpar S, Shen L, Wang X, Schilsky RL. Integrating biomarkers in colorectal cancer trials in the West and China. Nat Rev Clin Oncol. 2015 Sep; 12(9):553-60. PMID: 25963094.
      View in: PubMed
    64. Ratain MJ, Geary D, Undevia SD, Coronado C, Alfaro V, Iglesias JL, Schilsky RL, Miguel-Lillo B. First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. Invest New Drugs. 2015 Aug; 33(4):901-10. PMID: 25947566.
      View in: PubMed
    65. Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol. 2015 Aug; 26(8):1791-8. PMID: 25908602.
      View in: PubMed
    66. McClellan MB, Daniel GW, Dickson D, Perlmutter J, Berger DP, Miller V, Nussbaum S, Malin J, Romine MH, Schilsky RL. Improving evidence developed from population-level experience with targeted agents. Clin Pharmacol Ther. 2015 May; 97(5):478-87. PMID: 25676878.
      View in: PubMed
    67. Mendelsohn J, Ringborg U, Schilsky R. Innovative clinical trials for development of personalized cancer medicine. Mol Oncol. 2015 May; 9(5):933-4. PMID: 25772590.
      View in: PubMed
    68. Marrone M, Schilsky RL, Liu G, Khoury MJ, Freedman AN. Opportunities for translational epidemiology: the important role of observational studies to advance precision oncology. Cancer Epidemiol Biomarkers Prev. 2015 Mar; 24(3):484-9. PMID: 25750251.
      View in: PubMed
    69. Fleming GF, Schumm P, Friberg G, Ratain MJ, Njiaju UO, Schilsky RL. Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion. BMC Cancer. 2015 Feb 18; 15:69. PMID: 25885822.
      View in: PubMed
    70. Schully SD, Carrick DM, Mechanic LE, Srivastava S, Anderson GL, Baron JA, Berg CD, Cullen J, Diamandis EP, Doria-Rose VP, Goddard KA, Hankinson SE, Kushi LH, Larson EB, McShane LM, Schilsky RL, Shak S, Skates SJ, Urban N, Kramer BS, Khoury MJ, Ransohoff DF. Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. J Natl Cancer Inst. 2015 Apr; 107(4). PMID: 25688116.
      View in: PubMed
    71. Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809. PMID: 25605863.
      View in: PubMed
    72. Lamont EB, Schilsky RL, He Y, Muss H, Cohen HJ, Hurria A, Meilleur A, Kindler HL, Venook A, Lilenbaum R, Niell H, Goldberg RM, Joffe S. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). J Natl Cancer Inst. 2015 Jan; 107(1):336. PMID: 25432408.
      View in: PubMed
    73. Schilsky RL. Moving from evaluation to value in cancer care. Clin Cancer Res. 2015 Mar 01; 21(5):947-9. PMID: 25336697.
      View in: PubMed
    74. Hurria A, Dale W, Mooney M, Rowland JH, Ballman KV, Cohen HJ, Muss HB, Schilsky RL, Ferrell B, Extermann M, Schmader KE, Mohile SG. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014 Aug 20; 32(24):2587-94. PMID: 25071116.
      View in: PubMed
    75. Kolacevski A, Mann JT, Hauser R, Schilsky RL. Using Big Data to Track Trends in Medical Practice. J Oncol Pract. 2015 01; 11(1):69-70. PMID: 25139800.
      View in: PubMed
    76. Minasian L, Rosen O, Auclair D, Rahman A, Pazdur R, Schilsky RL. Optimizing dosing of oncology drugs. Clin Pharmacol Ther. 2014 Nov; 96(5):572-9. PMID: 25105705.
      View in: PubMed
    77. Schilsky RL. Reply to F.E. Vera-Badillo et al. J Clin Oncol. 2014 Oct 01; 32(28):3198. PMID: 25092782.
      View in: PubMed
    78. Schilsky RL. ASCO's initiative to define value in cancer care. Am J Manag Care. 2014 Aug; 20(11 Spec No.):E1. PMID: 25618157.
      View in: PubMed
    79. Schilsky RL. Drivers of change in cancer care. J Oncol Pract. 2014 Sep; 10(5):315-6. PMID: 25052500.
      View in: PubMed
    80. Schnipper LE, Schilsky RL, Hoverman JR, Raghavan D, Lyman GH, Wollins DS, Blayney DW. Reply to L.k. Griffeth et al and J.E. Battley et al. J Clin Oncol. 2014 Sep 01; 32(25):2812-3. PMID: 25024078.
      View in: PubMed
    81. Innocenti F, Schilsky RL, Ramírez J, Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, Karrison T, Maitland ML, Salgia R, Ratain MJ. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014 Aug 01; 32(22):2328-34. PMID: 24958824.
      View in: PubMed
    82. Schilsky RL, Michels DL, Kearbey AH, Yu PP, Hudis CA. Building a rapid learning health care system for oncology: the regulatory framework of CancerLinQ. J Clin Oncol. 2014 Aug 01; 32(22):2373-9. PMID: 24912897.
      View in: PubMed
    83. Mayer RJ, Venook AP, Schilsky RL. Progress against GI cancer during the American Society of Clinical Oncology's first 50 years. J Clin Oncol. 2014 May 20; 32(15):1521-30. PMID: 24752046.
      View in: PubMed
    84. Schilsky RL. Implementing personalized cancer care. Nat Rev Clin Oncol. 2014 07; 11(7):432-8. PMID: 24687035.
      View in: PubMed
    85. Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014 Apr 20; 32(12):1277-80. PMID: 24638016.
      View in: PubMed
    86. Tsimberidou AM, Eggermont AM, Schilsky RL. Precision cancer medicine: the future is now, only better. Am Soc Clin Oncol Educ Book. 2014; 61-9. PMID: 24857061.
      View in: PubMed
    87. Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain V, Davidson B, Siegler M, Caplin M, Solcia E, Schilsky R. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014 Jan; 15(1):e8-21. PMID: 24384494.
      View in: PubMed
    88. Schnipper LE, Lyman GH, Blayney DW, Hoverman JR, Raghavan D, Wollins DS, Schilsky RL. American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol. 2013 Dec 01; 31(34):4362-70. PMID: 24170249.
      View in: PubMed
    89. Schilsky RL. Wither the cooperative groups? J Clin Oncol. 2014 Jan 20; 32(3):251-4. PMID: 24043728.
      View in: PubMed
    90. Schilsky RL. Highlights from the 2013 WIN Symposium: personalised cancer therapy from innovation to implementation. Ecancermedicalscience. 2013; 7:344. PMID: 24009643.
      View in: PubMed
    91. Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DG, McCormack R, Newcomer L, Pothier K, Ransohoff D, Schilsky RL, Sigal E, Taube SE, Tunis SR. Breaking a vicious cycle. Sci Transl Med. 2013 Jul 31; 5(196):196cm6. PMID: 23903752.
      View in: PubMed
    92. Sharma MR, Karrison TG, Kell B, Wu K, Turcich M, Geary D, Kang SP, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen EE. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67. PMID: 23553850.
      View in: PubMed
    93. Wilson WH, Schenkein DP, Jernigan CL, Woodcock J, Schilsky RL. Reevaluating the accelerated approval process for oncology drugs. Clin Cancer Res. 2013 Jun 01; 19(11):2804-9. PMID: 23553847.
      View in: PubMed
    94. Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, Frankel W, Clark-Langone K, Millward C, Shak S, Goldberg RM, Mahmoud NN, Warren RS, Schilsky RL, Bertagnolli MM. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013 May 10; 31(14):1775-81. PMID: 23530100.
      View in: PubMed
    95. Conti RM, Bernstein AC, Villaflor VM, Schilsky RL, Rosenthal MB, Bach PB. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol. 2013 Mar 20; 31(9):1134-9. PMID: 23423747.
      View in: PubMed
    96. Schilsky RL. Publicly funded clinical trials and the future of cancer care. Oncologist. 2013; 18(2):232-8. PMID: 23363807.
      View in: PubMed
    97. Tsimberidou AM, Ringborg U, Schilsky RL. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. Am Soc Clin Oncol Educ Book. 2013; 118-25. PMID: 23714475.
      View in: PubMed
    98. Hahn OM, Schilsky RL. Randomized controlled trials and comparative effectiveness research. J Clin Oncol. 2012 Dec 01; 30(34):4194-201. PMID: 23071239.
      View in: PubMed
    99. Schilsky RL. Targeted therapy for cancer: asking the right questions. Oncology (Williston Park). 2012 Oct; 26(10):947-9. PMID: 23176006.
      View in: PubMed
    100. Schilsky RL. Scarcity of vital oncology drugs: finding long-term solutions. Clin Adv Hematol Oncol. 2012 Sep; 10(9):597-9. PMID: 23073126.
      View in: PubMed
    101. Schilsky RL. Advanced clinical trials for China. Chin Clin Oncol. 2012 Sep; 1(1):3. PMID: 25842061.
      View in: PubMed
    102. Dale W, Mohile SG, Eldadah BA, Trimble EL, Schilsky RL, Cohen HJ, Muss HB, Schmader KE, Ferrell B, Extermann M, Nayfield SG, Hurria A. Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J Natl Cancer Inst. 2012 Apr 18; 104(8):581-9. PMID: 22457474.
      View in: PubMed
    103. Schilsky RL, Doroshow JH, Leblanc M, Conley BA. Development and use of integral assays in clinical trials. Clin Cancer Res. 2012 Mar 15; 18(6):1540-6. PMID: 22422406.
      View in: PubMed
    104. Mendelsohn J, Ringborg U, Schilsky RL. Personalized cancer medicine - a strategy to counteract an increasing cancer challenge. Mol Oncol. 2012 Apr; 6(2):109-10. PMID: 22507633.
      View in: PubMed
    105. Katz ML, Archer LE, Peppercorn JM, Kereakoglow S, Collyar DE, Burstein HJ, Schilsky RL, Partridge AH. Patient advocates' role in clinical trials: perspectives from Cancer and Leukemia Group B investigators and advocates. Cancer. 2012 Oct 01; 118(19):4801-5. PMID: 22392584.
      View in: PubMed
    106. Sharma MR, Schilsky RL. Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol. 2011 Dec 06; 9(4):208-14. PMID: 22143142.
      View in: PubMed
    107. Innocenti F, Owzar K, Cox NL, Evans P, Kubo M, Zembutsu H, Jiang C, Hollis D, Mushiroda T, Li L, Friedman P, Wang L, Glubb D, Hurwitz H, Giacomini KM, McLeod HL, Goldberg RM, Schilsky RL, Kindler HL, Nakamura Y, Ratain MJ. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res. 2012 Jan 15; 18(2):577-84. PMID: 22142827.
      View in: PubMed
    108. Schilsky RL. Drug approval challenges in the age of personalized cancer treatment. Per Med. 2011 Nov; 8(6):633-640. PMID: 29776208.
      View in: PubMed
    109. Ambrose LF, Freedman J, Buetow K, Friend S, Schilsky RL. Using patient-initiated study participation in the development of evidence for personalized cancer therapy. Clin Cancer Res. 2011 Nov 01; 17(21):6651-7. PMID: 22046027.
      View in: PubMed
    110. Maitland ML, Schilsky RL. Clinical trials in the era of personalized oncology. CA Cancer J Clin. 2011 Nov-Dec; 61(6):365-81. PMID: 22034206.
      View in: PubMed
    111. Rimm DL, Nielsen TO, Jewell SD, Rohrer DC, Broadwater G, Waldman F, Mitchell KA, Singh B, Tsongalis GJ, Frankel WL, Magliocco AM, Lara JF, Hsi ED, Bleiweiss IJ, Badve SS, Chen B, Ravdin PM, Schilsky RL, Thor A, Berry DA. Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. J Clin Oncol. 2011 Jun 01; 29(16):2282-90. PMID: 21519016.
      View in: PubMed
    112. Schilsky RL, Crowther M. Update in hematology and oncology: evidence published in 2010. Ann Intern Med. 2011 Apr 05; 154(7):487-94. PMID: 21464351.
      View in: PubMed
    113. Schilsky RL. Tumor heterogeneity as the foundation of personalized cancer treatment. Semin Oncol. 2011 Apr; 38(2):171-2. PMID: 21421107.
      View in: PubMed
    114. Schilsky RL. Accrual to cancer clinical trials in the era of molecular medicine. Sci Transl Med. 2011 Mar 23; 3(75):75cm9. PMID: 21430267.
      View in: PubMed
    115. Mendelsohn J, Tursz T, Schilsky RL, Lazar V. WIN Consortium--challenges and advances. Nat Rev Clin Oncol. 2011 Mar; 8(3):133-4. PMID: 21364685.
      View in: PubMed
    116. Cohen EE, Schilsky RL. The next phase of chemoprevention research. Cancer Prev Res (Phila). 2011 Mar; 4(3):293-5. PMID: 21372026.
      View in: PubMed
    117. Shapiro CL, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, Sikov W, Winer E, Burstein HJ, Hudis C, Isaacs C, Schilsky R, Paskett E. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011 Mar; 47(5):683-9. PMID: 21324674.
      View in: PubMed
    118. McClellan M, Benner J, Schilsky R, Epstein D, Woosley R, Friend S, Sidransky D, Geoghegan C, Kessler D. An accelerated pathway for targeted cancer therapies. Nat Rev Drug Discov. 2011 02; 10(2):79-80. PMID: 21283090.
      View in: PubMed
    119. Sharma MR, Schilsky RL. GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy. Nat Rev Clin Oncol. 2011 Feb; 8(2):70-2. PMID: 21278772.
      View in: PubMed
    120. O'Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii-Saab T, Pluard T, Douglas K, Abou-Alfa GK, Kindler HL, Schilsky RL, Goldberg RM. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist. 2010; 15(12):1310-9. PMID: 21148613.
      View in: PubMed
    121. Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, Nelson SA, Weinshilboum RM, Ratain MJ, McLeod HL, Epstein RS, Ginsburg GS, Schilsky RL, Liu G, Flockhart DA, Ulrich CM, Davis RL, Lesko LJ, Zineh I, Randhawa G, Ambrosone CB, Relling MV, Rothman N, Xie H, Spitz MR, Ballard-Barbash R, Doroshow JH, Minasian LM. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705. PMID: 20944079.
      View in: PubMed
    122. Kaiser LD, Melemed AS, Preston AJ, Chaudri Ross HA, Niedzwiecki D, Fyfe GA, Gough JM, Bushnell WD, Stephens CL, Mace MK, Abrams JS, Schilsky RL. Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications. J Clin Oncol. 2010 Dec 01; 28(34):5046-53. PMID: 20921453.
      View in: PubMed
    123. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010 Aug 01; 28(22):3617-22. PMID: 20606091.
      View in: PubMed
    124. Gangadhar T, Schilsky RL. Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol. 2010 Jun; 7(6):318-25. PMID: 20440283.
      View in: PubMed
    125. Schilsky RL. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov. 2010 05; 9(5):363-6. PMID: 20431568.
      View in: PubMed
    126. Potti A, Schilsky RL, Nevins JR. Refocusing the war on cancer: the critical role of personalized treatment. Sci Transl Med. 2010 Apr 21; 2(28):28cm13. PMID: 20410527.
      View in: PubMed
    127. Peppercorn J, Shapira I, Collyar D, Deshields T, Lin N, Krop I, Grunwald H, Friedman P, Partridge AH, Schilsky RL, Bertagnolli MM. Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol. 2010 May 20; 28(15):2635-40. PMID: 20406927.
      View in: PubMed
    128. Menter DG, Schilsky RL, DuBois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res. 2010 Mar 01; 16(5):1384-90. PMID: 20179228.
      View in: PubMed
    129. Abrams J, Erwin R, Fyfe G, Schilsky RL. Data submission standards and evidence requirements. Oncologist. 2010; 15(5):488-91. PMID: 20489185.
      View in: PubMed
    130. Schilsky RL, Allen J, Benner J, Sigal E, McClellan M. Commentary: tackling the challenges of developing targeted therapies for cancer. Oncologist. 2010; 15(5):484-7. PMID: 20489184.
      View in: PubMed
    131. de Gramont A, Haller DG, Sargent DJ, Tabernero J, Matheson A, Schilsky RL. Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program. J Clin Oncol. 2010 Feb 01; 28(4):527-30. PMID: 19841311.
      View in: PubMed
    132. Innocenti F, Schilsky RL. Translating the cancer genome into clinically useful tools and strategies. Dis Model Mech. 2009 Sep-Oct; 2(9-10):426-9. PMID: 19726797.
      View in: PubMed
    133. Goss E, Link MP, Bruinooge SS, Lawrence TS, Tepper JE, Runowicz CD, Schilsky RL. The impact of the privacy rule on cancer research: variations in attitudes and application of regulatory standards. J Clin Oncol. 2009 Aug 20; 27(24):4014-20. PMID: 19620480.
      View in: PubMed
    134. Schilsky RL. Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. J Clin Oncol. 2009 Aug 10; 27(23):3725-30. PMID: 19581526.
      View in: PubMed
    135. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009 Apr 20; 27(12):2091-6. PMID: 19188670.
      View in: PubMed
    136. Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, Sawaya R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2009 Feb 10; 27(5):812-26. PMID: 19103723.
      View in: PubMed
    137. Schilsky RL. Join ASCO in Welcoming Dr John Cox As Editor-in-Chief. J Oncol Pract. 2008 Nov; 4(6):266. PMID: 20856754.
      View in: PubMed
    138. Perry MC, Comis RL, Schilsky RL. Introduction: contributions of the cooperative groups. Semin Oncol. 2008 Oct; 35(5):459. PMID: 18929144.
      View in: PubMed
    139. Green MR, George SL, Schilsky RL. Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B. Semin Oncol. 2008 Oct; 35(5):470-83. PMID: 18929146.
      View in: PubMed
    140. Strauss GM, Herndon JE, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008 Nov 01; 26(31):5043-51. PMID: 18809614.
      View in: PubMed
    141. Schilsky RL, Gordon G, Gilmer TM, Courtneidge SA, Matrisian LM, Grad O, Nelson WG. The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics). Clin Cancer Res. 2008 Sep 15; 14(18):5685-91. PMID: 18794076.
      View in: PubMed
    142. Schilsky RL. How not to treat cancer. Lancet Oncol. 2008 Jun; 9(6):504-5. PMID: 18510981.
      View in: PubMed
    143. Bressler LR, Schilsky RL. Collaboration between cooperative groups and industry. J Oncol Pract. 2008 May; 4(3):140-1. PMID: 20856620.
      View in: PubMed
    144. Zon R, Meropol NJ, Catalano RB, Schilsky RL. American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol. 2008 May 20; 26(15):2562-7. PMID: 18390967.
      View in: PubMed
    145. Lamont EB, Herndon JE, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Med Care. 2008 Mar; 46(3):303-8. PMID: 18388845.
      View in: PubMed
    146. Daugherty CK, Ratain MJ, Emanuel EJ, Farrell AT, Schilsky RL. Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol. 2008 Mar 10; 26(8):1371-8. PMID: 18227527.
      View in: PubMed
    147. Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner J, Demetri GD, Curran W, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey S, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Davidson NE, Schilsky RL, Lichter AS. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2008 Jan 10; 26(2):313-25. PMID: 18086794.
      View in: PubMed
    148. Posner MC, Niedzwiecki D, Venook AP, Hollis DR, Kindler HL, Martin EW, Schilsky RL, Goldberg RM, Mayer RJ. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann Surg Oncol. 2008 Jan; 15(1):158-64. PMID: 18008108.
      View in: PubMed
    149. Young RC, Friedman MA, Schilsky RL, Sigal EV. Drug safety and drug efficacy: two sides of the same coin. Clin Cancer Res. 2007 May 01; 13(9):2533-4. PMID: 17473179.
      View in: PubMed
    150. Kelloff GJ, Sullivan DM, Wilson W, Cheson B, Juweid M, Mills GQ, Zelenetz AD, Horning SJ, Weber W, Sargent DJ, Dodd L, Korn E, Armitage J, Schilsky R, Christian M, O'connor OA, Wang SJ, Farrell AT, Pazdur R, Graham M, Wahl RL, Larson SM, Kostakoglu L, Daube-Witherspoon M, Gastonis C, Siegel BA, Shankar LK, Lee DB, Higley HR, Sigman CC, Carucci D, Timko D, deGennaro LJ, Sigal E, Barker A, Woodcock J. FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol. 2007 Mar; 14(3):330-9. PMID: 17307666.
      View in: PubMed
    151. Yong WP, Desai AA, Innocenti F, Ramirez J, Shepard D, Kobayashi K, House L, Fleming GF, Vogelzang NJ, Schilsky RL, Ratain MJ. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2007 Nov; 60(6):811-9. PMID: 17308893.
      View in: PubMed
    152. Schilsky RL. Target practice: oncology drug development in the era of genomic medicine. Clin Trials. 2007; 4(2):163-6; discussion 173-7. PMID: 17456516.
      View in: PubMed
    153. Mauer AM, Rich ES, Schilsky RL. The role of cooperative groups in cancer clinical trials. Cancer Treat Res. 2007; 132:111-29. PMID: 17305018.
      View in: PubMed
    154. Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ, Eisenberg BL, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Reaman GH, Sawaya R, Schilsky RL, Schuchter LM, Sweetenham JW, Vahdat LT, Winn RJ. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2007 Jan 01; 25(1):146-62. PMID: 17158528.
      View in: PubMed
    155. Dilts DM, Sandler AB, Baker M, Cheng SK, George SL, Karas KS, McGuire S, Menon GS, Reusch J, Sawyer D, Scoggins M, Wu A, Zhou K, Schilsky RL. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. J Clin Oncol. 2006 Oct 01; 24(28):4553-7. PMID: 17008694.
      View in: PubMed
    156. Lamont EB, Herndon JE, Weeks JC, Henderson IC, Earle CC, Schilsky RL, Christakis NA. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst. 2006 Sep 20; 98(18):1335-8. PMID: 16985253.
      View in: PubMed
    157. Bial AK, Schilsky RL, Sachs GA. Evaluation of cognition in cancer patients: special focus on the elderly. Crit Rev Oncol Hematol. 2006 Dec; 60(3):242-55. PMID: 16860995.
      View in: PubMed
    158. Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Nelson H, Whittom R, Hantel A, Schilsky RL, Fuchs CS. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006 Aug 01; 24(22):3535-41. PMID: 16822843.
      View in: PubMed
    159. Schilsky RL, McIntyre OR, Holland JF, Frei E. A concise history of the cancer and leukemia group B. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3553s-5s. PMID: 16740784.
      View in: PubMed
    160. Ratain MJ, Miller AA, McLeod HL, Venook AP, Egorin MJ, Schilsky RL. The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3612s-6s. PMID: 16740794.
      View in: PubMed
    161. Friberg G, Schilsky RL. Is oral tegafur with leucovorin equivalent to intravenous 5-fluorouracil and leucovorin in colorectal cancer? Nat Clin Pract Oncol. 2006 May; 3(5):240-1. PMID: 16682999.
      View in: PubMed
    162. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006 Feb; 33(1):15-49. PMID: 16473643.
      View in: PubMed
    163. Lamont EB, Herndon JE, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005 Jul 20; 97(14):1080-3. PMID: 16030306.
      View in: PubMed
    164. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O'shaughnessy J, Guyton KZ, Mankoff DA, Shankar L, Larson SM, Sigman CC, Schilsky RL, Sullivan DC. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005 Apr 15; 11(8):2785-808. PMID: 15837727.
      View in: PubMed
    165. Desai AA, Schilsky RL, Young A, Janisch L, Stadler WM, Vogelzang NJ, Cadden S, Wright JA, Ratain MJ. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol. 2005 Jun; 16(6):958-65. PMID: 15824081.
      View in: PubMed
    166. Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG, Schuster MW, Marks LB, Cirrincione C, Norton L, Henderson IC, Schilsky RL, Hurd DD. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005 Apr 01; 23(10):2191-200. PMID: 15767638.
      View in: PubMed
    167. Schilsky RL. First-line treatment options for patients with metastatic colorectal cancer. Nat Clin Pract Oncol. 2004 Dec; 1(2):70-1. PMID: 16264820.
      View in: PubMed
    168. Goldberg RM, Venook AP, Schilsky RL. Cetuximab in the treatment of colorectal cancer. Clin Adv Hematol Oncol. 2004 Nov; 2(11):1-10; quiz 11-12. PMID: 16170891.
      View in: PubMed
    169. Undevia SD, Kindler HL, Janisch L, Olson SC, Schilsky RL, Vogelzang NJ, Kimmel KA, Macek TA, Ratain MJ. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol. 2004 Nov; 15(11):1705-11. PMID: 15520075.
      View in: PubMed
    170. Innocenti F, Undevia SD, Ramírez J, Mani S, Schilsky RL, Vogelzang NJ, Prado M, Ratain MJ. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther. 2004 Nov; 76(5):490-502. PMID: 15536463.
      View in: PubMed
    171. Taube SE, Gion M, Schilsky RL. 3rd EORTC-NCI International Meeting on Cancer Molecular Markers: From Discovery to Clinical Practice. Expert Rev Mol Diagn. 2004 Jul; 4(4):431-3. PMID: 15225090.
      View in: PubMed
    172. Helft PR, Schilsky RL, Hoke FJ, Williams D, Kindler HL, Sprague E, DeWitte M, Martino HK, Erickson J, Pandite L, Russo M, Lambert JM, Howard M, Ratain MJ. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 01; 10(13):4363-8. PMID: 15240523.
      View in: PubMed
    173. Kelloff GJ, Bast RC, Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Vande Woude GF. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res. 2004 Jun 01; 10(11):3881-4. PMID: 15173097.
      View in: PubMed
    174. Kelloff GJ, Schilsky RL, Alberts DS, Day RW, Guyton KZ, Pearce HL, Peck JC, Phillips R, Sigman CC. Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs. Clin Cancer Res. 2004 Jun 01; 10(11):3908-18. PMID: 15173100.
      View in: PubMed
    175. Partridge AH, Hackett N, Blood E, Gelman R, Joffe S, Bauer-Wu S, Knudsen K, Emmons K, Collyar D, Schilsky RL, Winer EP. Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants. J Natl Cancer Inst. 2004 Apr 21; 96(8):629-32. PMID: 15100341.
      View in: PubMed
    176. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res. 2004 Apr 15; 10(8):2584-6. PMID: 15102658.
      View in: PubMed
    177. Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004 Mar 22; 90(6):1190-7. PMID: 15026800.
      View in: PubMed
    178. Schilsky RL. Are targeted therapies really targeted? Clin Adv Hematol Oncol. 2003 Dec; 1(12):722-3. PMID: 16258475.
      View in: PubMed
    179. Schilsky RL. Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients? J Clin Oncol. 2003 Oct 15; 21(20):3718-20. PMID: 12963701.
      View in: PubMed
    180. Fleming GF, Schilsky RL, Schumm LP, Meyerson A, Hong AM, Vogelzang NJ, Ratain MJ. Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Ann Oncol. 2003 Jul; 14(7):1142-7. PMID: 12853359.
      View in: PubMed
    181. Sawyer MB, Ratain MJ, Bertucci D, Smith RP, Schilsky RL, Vogelzang NJ, Shulman K, Douglass EC, Fleming GF. Phase I study of an oral formulation of ZD9331 administered daily for 28 days. J Clin Oncol. 2003 May 01; 21(9):1859-65. PMID: 12721264.
      View in: PubMed
    182. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):976-83. PMID: 12637460.
      View in: PubMed
    183. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003 Mar 06; 348(10):883-90. PMID: 12621132.
      View in: PubMed
    184. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15; 21(8):1431-9. PMID: 12668651.
      View in: PubMed
    185. Fleming GF, Meropol NJ, Rosner GL, Hollis DR, Carson WE, Caligiuri M, Mortimer J, Tkaczuk K, Parihar R, Schilsky RL, Ratain MJ. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27. PMID: 12473581.
      View in: PubMed
    186. Maung K, Lee D, DeGrendele HC, Schilsky R, Chu E, Jain VK, Copur S. Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002. Clin Colorectal Cancer. 2002 Nov; 2(3):140-5. PMID: 12482329.
      View in: PubMed
    187. Schilsky RL, Taube SE. Tumor markers as clinical cancer tests--are we there yet? Semin Oncol. 2002 Jun; 29(3):211-2. PMID: 12063673.
      View in: PubMed
    188. Schilsky RL, Dressler LM, Bucci D, Monovich L, Jewell S, Suster S, Caligiuri MA, Kantoff PW, Compton C. Cooperative group tissue banks as research resources: the cancer and leukemia group B tissue repositories. Clin Cancer Res. 2002 May; 8(5):943-8. PMID: 12006505.
      View in: PubMed
    189. Schilsky RL. Inhibiting 5-fluorouracil breakdown: a broken down approach to 5-fluorouracil modulation. Clin Colorectal Cancer. 2002 May; 2(1):51-2. PMID: 12453336.
      View in: PubMed
    190. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Pérez-Manga G, Rosso R, Rougier P, Schilsky RL. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002 Apr; 13(4):566-75. PMID: 12056707.
      View in: PubMed
    191. Schilsky RL. End points in cancer clinical trials and the drug approval process. Clin Cancer Res. 2002 Apr; 8(4):935-8. PMID: 11948095.
      View in: PubMed
    192. Schilsky RL, Levin J, West WH, Wong A, Colwell B, Thirlwell MP, Ansari RH, Bell WN, White RL, Yates BB, McGuirt PV, Pazdur R. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol. 2002 Mar 15; 20(6):1519-26. PMID: 11896100.
      View in: PubMed
    193. Lamont EB, Lauderdale DS, Schilsky RL, Christakis NA. Construct validity of medicare chemotherapy claims: the case of 5FU. Med Care. 2002 Mar; 40(3):201-11. PMID: 11880793.
      View in: PubMed
    194. Shepard DR, Mani S, Kastrissios H, Learned-Coughlin S, Smith D, Ertel P, Magnum S, Janisch L, Fleming GF, Schilsky RL, Ratain MJ. Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. Cancer Chemother Pharmacol. 2002 May; 49(5):398-402. PMID: 11976834.
      View in: PubMed
    195. Schilsky RL, Bertucci D, Vogelzang NJ, Kindler HL, Ratain MJ. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002 Jan 15; 20(2):582-7. PMID: 11786589.
      View in: PubMed
    196. Dolan ME, Schilsky RL. Silence is golden: gene hypermethylation and survival in large-cell lymphoma. J Natl Cancer Inst. 2002 Jan 02; 94(1):6-7. PMID: 11773269.
      View in: PubMed
    197. Blanke CD, Shultz J, Cox J, Modiano M, Isaacs R, Kasimis B, Schilsky R, Fleagle J, Moore M, Kemeny N, Carlin D, Hammershaimb L, Haller D. A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer. Ann Oncol. 2002 Jan; 13(1):87-91. PMID: 11863117.
      View in: PubMed
    198. Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2(1):43-7. PMID: 11990381.
      View in: PubMed
    199. Lichtman SM, Petroni G, Schilsky RL, Johnson JL, Perri RT, Niedzwiecki D, Sklar J, Barcos M, Peterson BA. High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150. Leuk Lymphoma. 2001 Nov-Dec; 42(6):1255-64. PMID: 11911406.
      View in: PubMed
    200. Mani S, Vogelzang NJ, Bertucci D, Stadler WM, Schilsky RL, Ratain MJ. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001 Sep 15; 92(6):1567-76. PMID: 11745236.
      View in: PubMed
    201. Eng C, Kindler HL, Schilsky RL. Oral fluoropyrimidine treatment of colorectal cancer. Clin Colorectal Cancer. 2001 Aug; 1(2):95-103. PMID: 12445367.
      View in: PubMed
    202. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med. 2001 Jul 12; 345(2):144-5; author reply 146. PMID: 11450666.
      View in: PubMed
    203. Meropol NJ, Niedzwiecki D, Hollis D, Schilsky RL, Mayer RJ. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Cancer. 2001 Apr 01; 91(7):1256-63. PMID: 11283924.
      View in: PubMed
    204. Ewesuedo RB, Iyer L, Das S, Koenig A, Mani S, Vogelzang NJ, Schilsky RL, Brenckman W, Ratain MJ. Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer. J Clin Oncol. 2001 Apr 01; 19(7):2084-90. PMID: 11283142.
      View in: PubMed
    205. Goh BC, Ratain MJ, Bertucci D, Smith R, Mani S, Vogelzang NJ, Schilsky RL, Hutchison M, Smith M, Averbuch S, Douglass E. Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J Clin Oncol. 2001 Mar 01; 19(5):1476-84. PMID: 11230494.
      View in: PubMed
    206. Williams SF, Schilsky RL. Antineoplastic drugs administered during pregnancy. Semin Oncol. 2000 Dec; 27(6):618-22. PMID: 11130468.
      View in: PubMed
    207. Schilsky RL. Pharmacology and clinical status of capecitabine. Oncology (Williston Park). 2000 Sep; 14(9):1297-306; discussion 1309-11. PMID: 11033828.
      View in: PubMed
    208. Mani S, Hochster H, Beck T, Chevlen EM, O'Rourke MA, Weaver CH, Bell WN, White R, McGuirt C, Levin J, Hohneker J, Schilsky RL, Lokich J. Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2000 Aug; 18(15):2894-901. PMID: 10920138.
      View in: PubMed
    209. Schilsky RL, Dolan ME, Bertucci D, Ewesuedo RB, Vogelzang NJ, Mani S, Wilson LR, Ratain MJ. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res. 2000 Aug; 6(8):3025-31. PMID: 10955780.
      View in: PubMed
    210. Schilsky RL, Kindler HL. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul; 9(7):1635-49. PMID: 11060767.
      View in: PubMed
    211. Schilsky RL, Bukowski R, Burris H, Hochster H, O'Rourke M, Wall JG, Mani S, Bonny T, Levin J, Hohneker J. A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. Ann Oncol. 2000 Apr; 11(4):415-20. PMID: 10847459.
      View in: PubMed
    212. Lamont EB, Schilsky RL. The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res. 1999 Sep; 5(9):2289-96. PMID: 10499595.
      View in: PubMed
    213. Costanza ME, Weiss RB, Henderson IC, Norton L, Berry DA, Cirrincione C, Winer E, Wood WC, Frei E, McIntyre OR, Schilsky RL. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. J Clin Oncol. 1999 May; 17(5):1397-406. PMID: 10334524.
      View in: PubMed
    214. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer. 1999 Mar 15; 85(6):1261-8. PMID: 10189130.
      View in: PubMed
    215. Mani S, Sciortino D, Samuels B, Arrietta R, Schilsky RL, Vokes EE, Benner S. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Invest New Drugs. 1999; 17(1):97-101. PMID: 10555128.
      View in: PubMed
    216. Schilsky RL. Immunotherapy for colorectal cancer. Curr Oncol Rep. 1999; 1(2):147-8. PMID: 11122811.
      View in: PubMed
    217. Lilenbaum RC, Miller AA, Batist G, Bernard S, Hollis DR, Rosner GL, Egorin MJ, Schilsky RL, Ratain MJ. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study. J Clin Oncol. 1998 Oct; 16(10):3302-9. PMID: 9779705.
      View in: PubMed
    218. Schilsky RL. Biochemical and clinical pharmacology of 5-fluorouracil. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):13-8. PMID: 9830619.
      View in: PubMed
    219. Mani S, Kugler JW, Sciortino DF, Garcia JC, Ansari RH, Humerickhouse R, Michelassi F, Posner MC, Shulman KL, Schilsky RL, List M, Vokes EE, Benner S. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study. Ann Oncol. 1998 Sep; 9(9):1035-7. PMID: 9818081.
      View in: PubMed
    220. Dolan ME, Roy SK, Fasanmade AA, Paras PR, Schilsky RL, Ratain MJ. O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol. 1998 May; 16(5):1803-10. PMID: 9586894.
      View in: PubMed
    221. Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM, Schilsky RL. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol. 1998 May; 16(5):1811-9. PMID: 9586895.
      View in: PubMed
    222. Schilsky RL, Hohneker J, Ratain MJ, Janisch L, Smetzer L, Lucas VS, Khor SP, Diasio R, Von Hoff DD, Burris HA. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol. 1998 Apr; 16(4):1450-7. PMID: 9552051.
      View in: PubMed
    223. Vogelzang NJ, Mani S, Schilsky RL, Ansari RH, Taber D, Rhinehart SN, Garcia JC, Meyer SC, Mick R, Brockstein BE, Stadler WM, Ratain MJ, Vokes EE. Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Clin Cancer Res. 1998 Apr; 4(4):929-34. PMID: 9563886.
      View in: PubMed
    224. Mani S, Iyer L, Janisch L, Wang X, Fleming GF, Schilsky RL, Ratain MJ. Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol. 1998; 42(1):84-7. PMID: 9619763.
      View in: PubMed
    225. Mani S, Kugler JW, Knost JA, Sciortino DF, Gibbons J, Garcia JC, Ansari RH, Schilsky RL, Vokes EE. Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer. Invest New Drugs. 1998-1999; 16(3):275-8. PMID: 10360609.
      View in: PubMed
    226. Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R, Fisher RI, Peterson BA, Oken MM. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol. 1998 Jan; 16(1):19-26. PMID: 9440718.
      View in: PubMed
    227. Samuels BL, Hollis DR, Rosner GL, Trump DL, Shapiro CL, Vogelzang NJ, Schilsky RL. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. Clin Cancer Res. 1997 Nov; 3(11):1977-84. PMID: 9815587.
      View in: PubMed
    228. Chen L, Haraf D, Brachman D, Vokes E, Schilsky R. Concomitant 5-FU, hydroxyurea and cisplatin with external beam radiation therapy for locally advanced pancreatic cancer. Oncol Rep. 1997 Sep-Oct; 4(5):877-81. PMID: 21590158.
      View in: PubMed
    229. Cohen AM, Kelsen D, Saltz L, Minsky BD, Nelson H, Farouk R, Gunderson LL, Michelassi F, Arenas RB, Schilsky RL, Willet CG. Adjuvant therapy for colorectal cancer. Curr Probl Surg. 1997 Aug; 34(8):601-76. PMID: 9251585.
      View in: PubMed
    230. Ratain MJ, Skoog LA, O'Brien SM, Cooper N, Schilsky RL, Vogelzang NJ, Gerber M, Narang PK, Nicol SJ. Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule. Ann Oncol. 1997 Aug; 8(8):807-9. PMID: 9332692.
      View in: PubMed
    231. Miller AA, Rosner GL, Ratain MJ, Hollis DR, Green MR, Schilsky RL. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062). Clin Cancer Res. 1997 May; 3(5):719-25. PMID: 9815741.
      View in: PubMed
    232. Fleming GF, O'Brien SM, Hoffman PC, Vokes EE, Vogelzang NJ, Schilsky RL, Waggoner SE, Ratain MJ. Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin. Cancer Chemother Pharmacol. 1997; 39(3):227-32. PMID: 8996525.
      View in: PubMed
    233. Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, Henderson IC, Schilsky RL. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol. 1996 Nov; 14(11):3000-8. PMID: 8918498.
      View in: PubMed
    234. Greco FA, Figlin R, York M, Einhorn L, Schilsky R, Marshall EM, Buys SS, Froimtchuk MJ, Schuller J, Schuchter L, Buyse M, Ritter L, Man A, Yap AK. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol. 1996 Oct; 14(10):2674-81. PMID: 8874326.
      View in: PubMed
    235. Miller AA, Lilenbaum RC, Lynch TJ, Rosner GL, Ratain MJ, Green MR, Schilsky RL. Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. J Clin Oncol. 1996 Jun; 14(6):1964-5. PMID: 8656268.
      View in: PubMed
    236. Mick R, Vokes EE, Lestingi TM, Gray-Stern W, Fleming GF, Schilsky RL, Ratain MJ. Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1996 Mar; 59(3):349-59. PMID: 8653998.
      View in: PubMed
    237. Ratain MJ, Mick R, Janisch L, Berezin F, Schilsky RL, Vogelzang NJ, Kut M. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics. 1996 Feb; 6(1):93-101. PMID: 8845865.
      View in: PubMed
    238. Schilsky RL. Methotrexate: an effective agent for treating cancer and building careers. The polyglutamate era. Stem Cells. 1996 Jan; 14(1):29-32. PMID: 8820948.
      View in: PubMed
    239. Shulman K, Schilsky RL. Adjuvant therapy of colon cancer. Semin Oncol. 1995 Dec; 22(6):600-10. PMID: 8539635.
      View in: PubMed
    240. Lilenbaum RC, Ratain MJ, Miller AA, Hargis JB, Hollis DR, Rosner GL, O'Brien SM, Brewster L, Green MR, Schilsky RL. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. J Clin Oncol. 1995 Sep; 13(9):2230-7. PMID: 7545219.
      View in: PubMed
    241. Ratain MJ, Rosner G, Allen SL, Costanza M, Van Echo DA, Henderson IC, Schilsky RL. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol. 1995 Mar; 13(3):741-7. PMID: 7884434.
      View in: PubMed
    242. Miller AA, Hargis JB, Lilenbaum RC, Fields SZ, Rosner GL, Schilsky RL. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. J Clin Oncol. 1994 Dec; 12(12):2743-50. PMID: 7527456.
      View in: PubMed
    243. Janisch L, Mick R, Schilsky RL, Vogelzang NJ, O'Brien S, Kut M, Ratain MJ. Prognostic factors for survival in patients treated in phase I clinical trials. Cancer. 1994 Oct 01; 74(7):1965-73. PMID: 8082103.
      View in: PubMed
    244. Kobayashi K, Vogelzang NJ, O'Brien SM, Schilsky RL, Vokes EE, Ratain MJ. A phase I study of intermittent infusion cladribine in patients with solid tumors. Cancer. 1994 Jul 01; 74(1):168-73. PMID: 7911736.
      View in: PubMed
    245. Fleming GF, Ratain MJ, O'Brien SM, Schilsky RL, Hoffman PC, Richards JM, Vogelzang NJ, Kasunic DA, Earhart RH. Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. J Natl Cancer Inst. 1994 Mar 02; 86(5):368-72. PMID: 8308929.
      View in: PubMed
    246. Vogelzang NJ, Mick R, Janisch L, Berezin F, Schilsky RL, Ratain MJ. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). Cancer Res. 1994 Jan 01; 54(1):114-9. PMID: 8261430.
      View in: PubMed
    247. Mitchell RB, Dolan ME, Janisch L, Vogelzang NJ, Ratain MJ, Schilsky RL. Sequential therapy with dacarbazine and carmustine: a phase I study. Cancer Chemother Pharmacol. 1994; 34(6):509-14. PMID: 7923562.
      View in: PubMed
    248. Kilton LJ, Ashenhurst JB, Wade JL, Schilsky RL, Shiomoto G, Blough RR, French SL, Benson AB. Phase II study of fludarabine phosphate for gastric adenocarcinoma. An Illinois Cancer Center trial. Invest New Drugs. 1994; 12(2):163-6. PMID: 7532162.
      View in: PubMed
    249. Mullane MR, Schilsky RL, Carroll RB, Wade JL, Kilton LJ, Blough RR, Bauman A, French SL, Benson AB. Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial. Invest New Drugs. 1994; 12(3):267-70. PMID: 7896548.
      View in: PubMed
    250. Devine S, Ratain M, Janisch L, Richards J, Williams S, Schilsky R, Vogelzang N, Skosey C. Phase-I trial of Thiotepa, granulocyte-macrophage colony-stimulating factor and prednisone or pentoxifylline in patients with refractory solid tumors. Oncol Rep. 1994 Jan; 1(1):213-6. PMID: 21607339.
      View in: PubMed
    251. Ratain MJ, Mick R, Schilsky RL, Siegler M. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst. 1993 Oct 20; 85(20):1637-43. PMID: 8411243.
      View in: PubMed
    252. Samuels BL, Mick R, Vogelzang NJ, Williams SF, Schilsky RL, Safa AR, O'Brien SM, Ratain MJ. Modulation of vinblastine resistance with cyclosporine: a phase I study. Clin Pharmacol Ther. 1993 Oct; 54(4):421-9. PMID: 8222485.
      View in: PubMed
    253. Lichtman SM, Ratain MJ, Van Echo DA, Rosner G, Egorin MJ, Budman DR, Vogelzang NJ, Norton L, Schilsky RL. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. J Natl Cancer Inst. 1993 Aug 18; 85(16):1319-26. PMID: 8340944.
      View in: PubMed
    254. Vokes EE, Dolan ME, Krishnasamy S, Mick R, Ratain MJ, Berezin F, Brachman D, Whitman G, Schilsky RL, Charette J, et al. 5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis. Ann Oncol. 1993 Aug; 4(7):591-5. PMID: 8395874.
      View in: PubMed
    255. Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Vogelzang NJ, Lane LB. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res. 1993 May 15; 53(10 Suppl):2304-8. PMID: 8485716.
      View in: PubMed
    256. Kobayashi K, Schilsky RL. Update on biochemical modulation of chemotherapeutic agents. Oncology (Williston Park). 1993 May; 7(5):99-106, 109; discussion 110-4, 117. PMID: 8512789.
      View in: PubMed
    257. Schilsky RL, Janisch L, Berezin F, Mick R, Vogelzang NJ, Ratain MJ. Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer. Cancer Res. 1993 Mar 15; 53(6):1293-6. PMID: 7680282.
      View in: PubMed
    258. Schilsky RL, Ratain MJ, Janisch L, Vogelzang NJ, Lucas VS, Ravitch J, Hohneker JA, Clendeninn NJ, Tuttle RL. Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion. Cancer Chemother Pharmacol. 1993; 31(4):283-8. PMID: 8422691.
      View in: PubMed
    259. Vokes EE, O'Brien SM, Vogelzang NJ, Schilsky RL, Ratain MJ. Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study. Cancer Chemother Pharmacol. 1993; 32(5):347-52. PMID: 8339384.
      View in: PubMed
    260. Fleming GF, Schilsky RL. Antifolates: the next generation. Semin Oncol. 1992 Dec; 19(6):707-19. PMID: 1462168.
      View in: PubMed
    261. Myers SE, Schilsky RL. Prospects for fertility after cancer chemotherapy. Semin Oncol. 1992 Oct; 19(5):597-604. PMID: 1411656.
      View in: PubMed
    262. Schilsky RL. Biochemical pharmacology of chemotherapeutic drugs used as radiation enhancers. Semin Oncol. 1992 Aug; 19(4 Suppl 11):2-7. PMID: 1509277.
      View in: PubMed
    263. Schilsky RL, Ratain MJ, Vokes EE, Vogelzang NJ, Anderson J, Peterson BA. Laboratory and clinical studies of biochemical modulation by hydroxyurea. Semin Oncol. 1992 Jun; 19(3 Suppl 9):84-9. PMID: 1641659.
      View in: PubMed
    264. Vokes EE, Haraf DJ, Panje WR, Schilsky RL, Weichselbaum RR. Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. Semin Oncol. 1992 Jun; 19(3 Suppl 9):53-8. PMID: 1641658.
      View in: PubMed
    265. Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Williams SF, Smiddy J. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther. 1991 Nov; 50(5 Pt 1):573-9. PMID: 1934870.
      View in: PubMed
    266. Oster MW, Schilsky RL, Faraggi D, Korzun AH, Perry M, Moore A, Kalra J, Wood WC, Henderson IC. Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the Cancer and Leukemia Group B. Cancer. 1991 Oct 15; 68(8):1696-8. PMID: 1913511.
      View in: PubMed
    267. Schilsky RL, Faraggi D, Korzun A, Vogelzang N, Ellerton J, Wood W, Henderson IC. Phase II study of echinomycin in patients with advanced breast cancer: a report of Cancer and Leukemia Group B protocol 8641. Invest New Drugs. 1991 Aug; 9(3):269-72. PMID: 1783527.
      View in: PubMed
    268. Ratain MJ, Mick R, Schilsky RL, Vogelzang NJ, Berezin F. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol. 1991 Aug; 9(8):1480-6. PMID: 2072147.
      View in: PubMed
    269. Gradishar W, Vokes E, Schilsky R, Weichselbaum R, Panje W. Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience. Med Pediatr Oncol. 1991; 19(1):8-15. PMID: 1990260.
      View in: PubMed
    270. Vokes EE, Ratain MJ, Janisch L, Hoffman PC, Golomb HM, Schilsky RL. A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients. Eur J Cancer. 1991; 27(2):217-8. PMID: 1827293.
      View in: PubMed
    271. Vokes EE, Raschko JW, Vogelzang NJ, Warfield EE, Ratain MJ, Doroshow JH, Schilsky RL. Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study. Cancer Chemother Pharmacol. 1991; 28(1):69-73. PMID: 1828191.
      View in: PubMed
    272. Schilsky RL, Choi KE, Grayhack J, Grimmer D, Guarnieri C, Fullem L. Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J Clin Oncol. 1990 Dec; 8(12):2054-61. PMID: 2230897.
      View in: PubMed
    273. Ratain MJ, Schilsky RL, Conley BA, Egorin MJ. Pharmacodynamics in cancer therapy. J Clin Oncol. 1990 Oct; 8(10):1739-53. PMID: 2213109.
      View in: PubMed
    274. Schilsky RL, Ratain MJ. Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. J Natl Cancer Inst. 1990 Sep 05; 82(17):1411-5. PMID: 2388292.
      View in: PubMed
    275. Ringenberg QS, Propert KJ, Muss HB, Weiss RB, Schilsky RL, Modeas C, Perry MC, Norton L, Green M. Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report. Invest New Drugs. 1990 May; 8(2):221-6. PMID: 2166722.
      View in: PubMed
    276. Vokes EE, Schilsky RL, Weichselbaum RR, Kozloff MF, Panje WR. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1990 Feb; 8(2):241-7. PMID: 1688926.
      View in: PubMed
    277. Zacharski LR, Moritz TE, Haakenson CM, O'Donnell JF, Ballard HS, Johnson GJ, Ringenberg QS, Schilsky RL, Spaulding MB, Tornyos K, et al. Chronic calcium antagonist use in carcinoma of the lung and colon: a retrospective cohort observational study. Cancer Invest. 1990; 8(5):451-8. PMID: 2176124.
      View in: PubMed
    278. Lee PP, Schilsky RL. Inhibition of thymidylate synthase by the diastereoisomers of leucovorin. Cancer Chemother Pharmacol. 1990; 26(4):273-7. PMID: 2114950.
      View in: PubMed
    279. Green MR, Kramar A, Schilsky R, Stoopler M, Zimmer B, Richards F, Skarin A, Anderson JR. Platinum-based combination chemotherapy in advanced non-small cell lung cancer: a randomized phase II trial of the Cancer and Leukemia Group B. Med Pediatr Oncol. 1990; 18(3):197-202. PMID: 2158614.
      View in: PubMed
    280. Gradishar WJ, Schilsky RL. Ovarian function following radiation and chemotherapy for cancer. Semin Oncol. 1989 Oct; 16(5):425-36. PMID: 2678491.
      View in: PubMed
    281. Schilsky RL. Infertility in patients with testicular cancer: testis, tumor, or treatment? J Natl Cancer Inst. 1989 Aug 16; 81(16):1204-5. PMID: 2754737.
      View in: PubMed
    282. Hohl RJ, Schilsky RL. Nonmalignant complications of therapy for Hodgkin's disease. Hematol Oncol Clin North Am. 1989 Jun; 3(2):331-43. PMID: 2663831.
      View in: PubMed
    283. Vokes EE, Panje WR, Schilsky RL, Mick R, Awan AM, Moran WJ, Goldman MD, Tybor AG, Weichselbaum RR. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol. 1989 Jun; 7(6):761-8. PMID: 2715806.
      View in: PubMed
    284. Vokes EE, Schilsky RL, Weichselbaum RR, Guaspari A, Guarnieri CM, Whaling SM, Panje WR. Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer. Cancer. 1989 Mar 15; 63(6 Suppl):1048-53. PMID: 2783881.
      View in: PubMed
    285. Schilsky RL, Choi KE, Vokes EE, Guaspari A, Guarnieri C, Whaling S, Liebner MA. Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing. Cancer. 1989 Mar 15; 63(6 Suppl):1018-21. PMID: 2783878.
      View in: PubMed
    286. Ratain MJ, Schilsky RL, Choi KE, Guarnieri C, Grimmer D, Vogelzang NJ, Senekjian E, Liebner MA. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther. 1989 Mar; 45(3):226-33. PMID: 2920497.
      View in: PubMed
    287. Schilsky RL. Male fertility following cancer chemotherapy. J Clin Oncol. 1989 Mar; 7(3):295-7. PMID: 2645384.
      View in: PubMed
    288. Vokes EE, Schilsky RL, Choi KE, Magid DM, Guarnieri CM, Whaling SM, Ratain MJ, Weichselbaum RR, Panje WR. A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. Cancer. 1989 Jan 01; 63(1):30-6. PMID: 2910422.
      View in: PubMed
    289. Magid DM, Vokes EE, Schilsky RL, Guarnieri CM, Whaling SM, Weichselbaum RR, Panje WR. A randomized study of inpatient versus outpatient continuous intravenous infusion chemotherapy: psychosocial aspects. Sel Cancer Ther. 1989; 5(3):137-45. PMID: 2682877.
      View in: PubMed
    290. Ratain MJ, Schilsky RL, Wojack BR, Simon T, Senekjian EK, Vogelzang NJ. Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial. J Natl Cancer Inst. 1988 Nov 02; 80(17):1412-6. PMID: 3270508.
      View in: PubMed
    291. Ackland SP, Schilsky RL, Beckett MA, Weichselbaum RR. Synergistic cytotoxicity and DNA strand break formation by bromodeoxyuridine and bleomycin in human tumor cells. Cancer Res. 1988 Aug 01; 48(15):4244-9. PMID: 2455593.
      View in: PubMed
    292. Ratain MJ, Staubus AE, Schilsky RL, Malspeis L. Limited sampling models for amonafide (NSC 308847) pharmacokinetics. Cancer Res. 1988 Jul 15; 48(14):4127-30. PMID: 3383202.
      View in: PubMed
    293. Vokes EE, Panje WR, Weichselbaum RR, Schilsky RL, Moran WJ, Awan AM, Guarnieri CM. Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results. Otolaryngol Head Neck Surg. 1988 Apr; 98(4):295-8. PMID: 3132681.
      View in: PubMed
    294. Vokes EE, Choi KE, Schilsky RL, Moran WJ, Guarnieri CM, Weichselbaum RR, Panje WR. Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol. 1988 Apr; 6(4):618-26. PMID: 3258629.
      View in: PubMed
    295. Choi KE, Schilsky RL. Resolution of the stereoisomers of leucovorin and 5-methyltetrahydrofolate by chiral high-performance liquid chromatography. Anal Biochem. 1988 Feb 01; 168(2):398-404. PMID: 2834981.
      View in: PubMed
    296. Gradishar WJ, Schilsky RL. Effects of cancer treatment on the reproductive system. Crit Rev Oncol Hematol. 1988; 8(2):153-71. PMID: 3046766.
      View in: PubMed
    297. Williams SF, Schilsky RL, Ultmann JE, Samuels BL. The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of malignant lymphomas. Cancer Invest. 1988; 6(4):427-37. PMID: 3052703.
      View in: PubMed
    298. Vokes EE, Moran WJ, Awan AM, Schilsky RL, Goldman M, Sutton HG, Weichselbaum RR, Panje WR. Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer. NCI Monogr. 1988; (6):353-6. PMID: 3352782.
      View in: PubMed
    299. Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. J Clin Oncol. 1987 Dec; 5(12):2017-31. PMID: 3316519.
      View in: PubMed
    300. Bennett CL, Sinkule JA, Schilsky RL, Senekjian E, Choi KE. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res. 1987 Apr 01; 47(7):1952-6. PMID: 3815383.
      View in: PubMed
    301. Schilsky RL, Williams SF, Ultmann JE, Watson S. Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin's lymphoma. J Clin Oncol. 1987 Mar; 5(3):419-25. PMID: 3819808.
      View in: PubMed
    302. Schilsky RL, Davidson HS, Magid D, Daiter S, Golomb HM. Gonadal and sexual function in male patients with hairy cell leukemia: lack of adverse effects of recombinant alpha 2-interferon treatment. Cancer Treat Rep. 1987 Feb; 71(2):179-81. PMID: 3100036.
      View in: PubMed
    303. Schilsky RL. Clinical implications of tumor heterogeneity. Haematol Blood Transfus. 1987; 31:278-82. PMID: 3327773.
      View in: PubMed
    304. Ratain MJ, Schilsky RL. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Cancer Res. 1986 Sep; 46(9):4874. PMID: 2942243.
      View in: PubMed
    305. Schilsky RL, O'Laughlin K, Ratain MJ. Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer. Cancer Res. 1986 Aug; 46(8):4184-8. PMID: 3731086.
      View in: PubMed
    306. Schilsky RL. Tumor cell heterogeneity: implications for clinical practice. Semin Oncol. 1985 Sep; 12(3):203-6. PMID: 4048963.
      View in: PubMed
    307. Schilsky RL, Green MR, Anderson J. Cytarabine-cis-platin interactions in patients with advanced cancer. Semin Oncol. 1985 Jun; 12(2 Suppl 3):171-6. PMID: 4040265.
      View in: PubMed
    308. Schilsky RL, Ordway FS. Simultaneous determination of cytosine arabinoside, its nucleotides and metabolites by ion-pair high-performance liquid chromatography. J Chromatogr. 1985 Jan 11; 337(1):63-71. PMID: 3980658.
      View in: PubMed
    309. Schilsky RL, Ordway FS. Insulin effects on methotrexate polyglutamate synthesis and enzyme binding in cultured human breast cancer cells. Cancer Chemother Pharmacol. 1985; 15(3):272-7. PMID: 2414022.
      View in: PubMed
    310. Schilsky RL, Muscato JJ, Muscato MS, Perry MC. Phase I clinical evaluation of cytarabine and cisplatin in patients with advanced cancer. Cancer Treat Rep. 1984 Sep; 68(9):1097-102. PMID: 6541094.
      View in: PubMed
    311. Schilsky RL, Jolivet J, Bailey BD, Chabner BA. Synthesis, binding and intracellular retention of methotrexate polyglutamates by cultured human breast cancer cells. Adv Exp Med Biol. 1983; 163:247-57. PMID: 6193688.
      View in: PubMed
    312. Jolivet J, Schilsky RL, Bailey BD, Chabner BA. The synthesis and retention of methotrexate polyglutamates in cultured human breast cancer cells. Ann N Y Acad Sci. 1982 Dec 10; 397:184-92. PMID: 6186175.
      View in: PubMed
    313. Schilsky RL, Barlock A, Ozols RF. Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep. 1982 Sep; 66(9):1767-9. PMID: 6889461.
      View in: PubMed
    314. Jolivet J, Schilsky RL, Bailey BD, Drake JC, Chabner BA. Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. J Clin Invest. 1982 Aug; 70(2):351-60. PMID: 6178756.
      View in: PubMed
    315. Schilsky RL, Kelley JA, Ihde DC, Howser DM, Cordes RS, Young RC. Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans. Cancer Res. 1982 Apr; 42(4):1582-6. PMID: 7060028.
      View in: PubMed
    316. Schilsky RL. Renal and metabolic toxicities of cancer chemotherapy. Semin Oncol. 1982 Mar; 9(1):75-83. PMID: 7200263.
      View in: PubMed
    317. Schilsky RL, Sherins RJ, Hubbard SM, Wesley MN, Young RC, DeVita VT. Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. Am J Med. 1981 Oct; 71(4):552-6. PMID: 7282743.
      View in: PubMed
    318. Schilsky RL, Bailey BD, Chabner BA. Characteristics of membrane transport of methotrexate by cultured human breast cancer cells. Biochem Pharmacol. 1981 Jun 15; 30(12):1537-42. PMID: 7023485.
      View in: PubMed
    319. Jolivet J, Schilsky RL. High-pressure liquid chromatography analysis of methotrexate polyglutamates in cultured human breast cancer cells. Biochem Pharmacol. 1981 Jun 01; 30(11):1387-90. PMID: 6168268.
      View in: PubMed
    320. Chabner BA, Donehower RC, Schilsky RL. Clinical pharmacology of methotrexate. Cancer Treat Rep. 1981; 65 Suppl 1:51-4. PMID: 6799198.
      View in: PubMed
    321. Schilsky RL, Lewis BJ, Sherins RJ, Young RC. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med. 1980 Jul; 93(1):109-14. PMID: 6994532.
      View in: PubMed
    322. Longo DL, Schilsky RL, Blei L, Cano R, Johnston GS, Young RC. Gallium-67 scanning: limited usefulness in staging patients with non-Hodgkin's lymphoma. Am J Med. 1980 May; 68(5):695-700. PMID: 6769331.
      View in: PubMed
    323. Schilsky RL, Bailey BD, Chabner BA. Methotrexate polyglutamate synthesis by cultured human breast cancer cells. Proc Natl Acad Sci U S A. 1980 May; 77(5):2919-22. PMID: 6156458.
      View in: PubMed
    324. Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC, Muggia FM. Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep. 1979 Sep-Oct; 63(9-10):1527-31. PMID: 387223.
      View in: PubMed
    325. Anderson T, Javadpour N, Schilsky R, Barlock A, Young RC. Chemotherapy for testicular cancer: current status of the National Cancer Institute Combined Modality Trial. Cancer Treat Rep. 1979 Sep-Oct; 63(9-10):1687-92. PMID: 91439.
      View in: PubMed
    326. Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med. 1979 Jun; 90(6):929-31. PMID: 375794.
      View in: PubMed
    Schilsky's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _